Moleculin Biotech, Inc. (MBRX) Analysts See $-0.14 EPS as of May, 21

Postado Mai 17, 2018

Wall Street predicts -17.65 % EPS growth as of May, 21. Last year's earnings per share was $-0.1, while now analysts expect change of 40.00 % down from current $-0.14 earnings per share. The company had a trading volume of 174,300 shares, compared to its average volume of 759,656. And last was posted on May 15, 2018, called "Moleculin Biotech, Inc".

MBRX has been the subject of several research reports. MBRX touched $1.7252 during the last trading session after $0.0148 change.Currently Moleculin Biotech, uptrending after 70.64% change in last May 16, 2017. MBRX outperformed the S&P500 by 59.09%. (NASDAQ:MBRX) news were announced by, and

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.

Moleculin Biotech, based in Houston, TX. The first one has "Moleculin Biotech, Inc". The next is "Moleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial" on May 03, 2018. The next is "Moleculin Biotech (MBRX) Enters Pact with BSP Pharmaceuticals for its Leukemia Drug Candidate" on April 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.